Skip to main content
SpringerLink
Log in

Vitamin E Analog α-TEA and Celecoxib Alone and Together Reduce Human MDA-MB-435-FL-GFP Breast Cancer Burden and Metastasis in Nude Mice

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

α-TEA, a nonhydrolyzable ether analog of vitamin E (RRR-α-tocopherol), and celecoxib, a specific COX-2 inhibitor, were delivered separately or in combination to investigate their anticancer properties, using MDA-MB-435-FL-GFP human breast cancer xenografts in nude mice. Liposomal formulated α-TEA administered as an aerosol and celecoxib fed at 500 or 1250 mg/kg diet for 31 days separately or in combination significantly reduced tumor volume in comparison to control (p < 0.001 for all treatment groups). Of special note, the combinations of α-TEA + celecoxib (1250) inhibited tumor volume significantly better than either single treatment (p < 0.001 and p < 0.001). Average number of macroscopic lung metastases were significantly reduced in all treatment groups in comparison to control, with the exception of celecoxib (500). Mean numbers of microscopic lung and lymph node metastases in all treatment groups were significantly lower than control. Furthermore, the mean number of microscopic lung metastases in the α-TEA+celecoxib (1250) group were significantly lower than either separate treatment. Analyses of 5 μm tumor sections showed that all treatments, with the exception of celecoxib (500) alone, significantly enhanced apoptosis (TUNEL) and significantly decreased cell proliferation (Ki-67). α-TEA and α-TEA + celecoxib (1250) treatments significantly reduced blood vessel density (CD-31) in comparison to control. These data show promise for combination α-TEA + celecoxib chemotherapy for breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ: Cancer statistics, 2004. CA Cancer J Clin 54:8–29, 2004

    Google Scholar 

  2. Lawson KA, Anderson K, Menchaca M, Atkinson J, Sun L, Knight V, Gilbert BE, Conti C, Sanders BG, Kline K: Novel vitamin E analogue decreases syngeneic mouse mammary tumor burden and reduces lung metastasis. Mol Cancer Ther 2:437–444, 2003

    Google Scholar 

  3. Shun M-C, Yu W, Gapor A, Parsons R, Atkinson J, Sanders BG, Kline K: Pro-apoptotic mechanisms of action of a novel vitamin E analog (a-TEA)and a naturally occurring form of vitamin E (d-tocotrienol)in MDA-MB-435 human breast cancer cells. Nutr Cancer 48(1):in press

  4. Hwang D, Scollard D, Byrne J, Levine E: Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Nat Cancer Inst 90:455–460, 1998

    Google Scholar 

  5. Alshafie GA, Abou-Issa HM, Seibert K, Harris RE: Chlemotherapeutic evaluation of cyclooxygenase-2 inhibitor,in a rat mammary tumor model Oncol Rep 7:1377–1381, 2000

    Google Scholar 

  6. Harris RE, Alshafie GA, Abou-Issa H, Seibert K: Chemoprevention of breast cancer in rats by Celecoxib, a cyclooxygenase-2 (COX-2)inhibitor. Cancer Res 60: 2101–2103, 2000

    Google Scholar 

  7. Blumenthal RD, Waskewich C, Goldenberg DM, Lew W, Flefleh C, Burton J: Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts. Clin Cancer Res 7: 3178–3185, 2001

    Google Scholar 

  8. Kundu N, Fulton AM: Selective cyclooxygenase (COX)-l or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res 62:2343–2346, 2002

    Google Scholar 

  9. Abou-Issa HM, Alshafie GA, Seibert K, Koki AT, Masferrer JL, Harris RE: Dose-response effects of COX-2 inhibitor, Celecoxib, on the chemoprevention of mammary carcinogenesis. Anticancer Res 21:3425–3432, 2001

    Google Scholar 

  10. Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C, Thaler HT, Muller WJ, Du B, Brown AM, Dannenberg AJ: Celecoxib, a selective cyclooxygenase-2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res 62:5405–5407, 2002

    Google Scholar 

  11. Lanza-Jacoby S, Miller S, Flynn J, Gallatig K, Daskalakis C, Masferrer JL, Zweifel BS, Sembhi H, Russo IH: The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice. Cancer Epidemiol Biomark Prev 12:1486–1491, 2003

    Google Scholar 

  12. Chang S-H, Liu CH, Conway R, Han DK, Nithipatikom K, Trifan OC, Lane TF, Hla T: Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase-2-induced breast cancer progression. PNAS 101:591–596, 2004

    Google Scholar 

  13. Liu XH, Rose DP: Differential expression and regulation of cyclooxygenase-1 and-2 in two human breast cancer cell lines. Cancer Res 56:5125–5127, 1996

    Google Scholar 

  14. Cuendet M, Pezzuto JM: The role of cyclooxygenase and lipoxygenase in cancer chemoprevention. Drug Metabol Drug Interact 17:109–157, 2000

    Google Scholar 

  15. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, Koki AT:COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89:2637–2645, 2000

    Google Scholar 

  16. Howe LR, Subbaramaiah RK, Brown AMC, Dannenberg AJ:Cyclooxygenase-2:a target for the prevention and treatment of breast cancer. Endocrine Relat Res 8:97–114, 2001

    Google Scholar 

  17. Tsujii M, DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2.Cell 83:493–501, 1995

    Google Scholar 

  18. Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC: Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 164:820–825, 2000

    Google Scholar 

  19. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60:1306–1311, 2000

    Google Scholar 

  20. Yu W, Israel K, Liao QY, Aldaz CM, Sanders BG, Kline K: Vitamin E succinate (VES)induces Fas sensitivity in human breast cancer cells: role for Mr 43,000 Fas in VES-triggered apoptosis. Cancer Res 59:953–961, 1999

    Google Scholar 

  21. Knight V, Koshkina NV, Waldrep JC, Giovanella BC, Gilbert BE: Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice. Cancer Chemother Pharmacol 44:177–186, 1999

    Google Scholar 

  22. Koshkina NV, Kleinerman ES, Waldrep C, Jia S, Worth LL, Gilbert BE, Knight V:9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastasis in mice. Clin Cancer Res 6:2876–2880,2000

    Google Scholar 

  23. Wang J, Sun L, Myeroff L, Wang X, Gentry LE, Yang J, Lian J, Zborowska E, Markowitz S, Willson JK, et al.: Demonstration that mutation of the type II transforming growth factor beta receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. J Biol Chem 270:22044–22049, 1995

    Google Scholar 

  24. Weidner N: Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 147:9–19, 1995

    Google Scholar 

  25. Chow LWC, Wong JLN, Toi M: Celecoxib anti-aromatase neoadjuvant (CAAN)trial for locally advanced breast cancer: preliminary report. J Steroid Biochem Mol Biol 86: 443–447, 2003

    Google Scholar 

  26. Davis TW, O'Neal JM, Pagel MD, Zweifel BS, Mehta PP, Heuvelman DM, Masferrer JL: Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E(2),a survival factor for tumor and associated vasculature. Cancer Res 64:279–285, 2004

    Google Scholar 

  27. Chun KS, Kim SH, Song YS, Surh YJ: Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin. Carcinogenesis 16:16, 2004

    Google Scholar 

  28. Agarwal B, Swaroop P, Protiva P, Raj SV, Shirin H, Holt PR:Cox-2 is needed but not sufficient for apoptosis induced by Cox-2 selective inhibitors in colon cancer cells. Apoptosis 8:649–654, 2003

    Google Scholar 

  29. Sheng GG, Shao J, Sheng H, Hooton EB, Isakson PC, Morrow JD, Coffey Jr RJ, DuBois RN, Beauchamp RD:A selective cyclooxygenase-2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells. Gastroenterology 113:1883–1891, 1997

    Google Scholar 

  30. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946–1952, 2000

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nutrition/A2703, University of Texas at Austin, Austin, TX

    Shuo Zhang, Karla A. Lawson & Kimberly Kline

  2. School of Biological Sciences, University of Texas at Austin, Austin

    Marla Simmons-Menchaca & Bob G. Sanders

  3. University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

    LuZhe Sun

Authors
  1. Shuo Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karla A. Lawson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marla Simmons-Menchaca
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. LuZhe Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bob G. Sanders
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kimberly Kline
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, S., Lawson, K.A., Simmons-Menchaca, M. et al. Vitamin E Analog α-TEA and Celecoxib Alone and Together Reduce Human MDA-MB-435-FL-GFP Breast Cancer Burden and Metastasis in Nude Mice. Breast Cancer Res Treat 87, 111–121 (2004). https://doi.org/10.1023/B:BREA.0000041593.69178.57

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:BREA.0000041593.69178.57

Search

Navigation